SmeNSECLOSED
Speciality Medicines IPO
₹117 – ₹117 · Issue Size ₹29.14 CrIPO Overview
Business Model
Competitive Advantages
- Some of the information presented below relating to our Company is derived from the Restated Financial
- Some of the quantitative factors which may form the basis for calculating the issue Price are as follows:
- I. Basic and diluted earnings per share ("EPS")
- Year ended Basic/Diluted EPS (in ₹) Weight
- For the period ended October 2025* 9.41 -
- Weighted Average 10.20 -
- *EPS are not annualised.
IPO Timeline
Objects of the Issue
| Purpose | Amount |
|---|---|
| Year 2023–24, raising a demand of excluding applicable interest. the company has submitted its response, | ₹0.09 Cr |
Strengths & Weaknesses
Strengths
- Some of the information presented below relating to our Company is derived from the Restated Financial
- Some of the quantitative factors which may form the basis for calculating the issue Price are as follows:
- I. Basic and diluted earnings per share ("EPS")
- Year ended Basic/Diluted EPS (in ₹) Weight
- For the period ended October 2025* 9.41 -
- Weighted Average 10.20 -
- *EPS are not annualised.
Management & Promoters
P
Parth GoyaniManaging Director
S
Sumit GoyaniWhole-time Director
K
Kalpesh PipaliyaChief Financial Officer
A
Anita KumawatCompany Secretary
Peer Comparison
| Company | P/E | EPS |
|---|---|---|
| Speciality Medicines IPO | — | — |
| Materiality Policy The policy adopted by our Board on June f | 10.0x | — |
Pre-IPO Financials
| Period | Revenue (Cr) | PAT (Cr) | Net Worth (Cr) | Total Assets (Cr) |
|---|---|---|---|---|
| 2006 | ₹0.35 Cr | ₹0.31 Cr | ₹0.15 Cr | ₹20.13 Cr |
| October 2025 | ₹0.07 Cr | ₹6.06 Cr | ₹36.47 Cr | — |
| March 2025 | ₹0.08 Cr | ₹8.61 Cr | ₹30.42 Cr | — |
| 2024 | ₹1.62 Cr | ₹2.93 Cr | ₹15.06 Cr | — |
| 2023 | ₹1.26 Cr | ₹1.7 Cr | ₹5.93 Cr | — |
About
One of the leading companies," Speciality Medicines" was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international ma
| Exchange | NSE |
| Issue Type | sme |
| Face Value | ₹10 per share |
Documents
rupiya.io is for research and education only. IPO data is sourced from public disclosures (DRHP/RHP). Not investment advice. Validate with SEBI-regulated disclosures before acting.